Abstract
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the medical community has faced major challanges that affect disease management in all areas. Dermatologists have to choose appropriate treatment strategy taking into consideration risk of infection COVID-19 in patients on systemic therapy of moderate to severe atopic dermatitis.
Out of a total of 15 of our patients with severe atopic eczema treated with dupilumab did not lead to loss of efficacy. Our patients were treated with the same effect of dupilumab therapy weeks and months after COVID-19 infections.
Most of our patients has experienced worsening of atopic dermatitis and mild course of COVID-19 infection, indepndently dupilumab was discontinued or not. Patients with mild course of COVID-19 infections continued with dupilumab therapy and did not observe any worsening of COVID-19 symptoms.
Our observations have confirmed the data from literature showing that dupilumab can be safely used during the COVID-19 pandemic.